We are proud to celebrate the exceptional achievements of Assoc. Prof. Dr. Adlinda Alip and her dedicated team at Universiti Malaya Medical Centre (UMMC) in the ASCENT-07 trial. This pivotal study investigates the efficacy of sacituzumab govitecan compared to the treatment of physician’s choice in patients with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer who have received prior endocrine therapy.
Activated on 16 February 2024, the trial achieved remarkable results with recruitment closing on 24 July 2024. UMMC successfully recruited 7 subjects in just five months, exceeding the initial target of 3 subjects—a 133% increase over the goal. Impressively, the first subject was screened within 5 days of site activation, demonstrating the team’s efficiency and dedication.
UMMC’s performance not only established it as the top enroller in Malaysia but also the top enroller across Southeast Asia for ASCENT-07. This achievement highlights the team’s exceptional operational capabilities and commitment to advancing clinical research.
We extend our deepest gratitude to Assoc. Prof. Dr. Adlinda Alip, Cryst Sari, and the entire UMMC team for their hard work and professionalism. Your contributions have been invaluable to the success of ASCENT-07.